Advertisement
U.S. Markets closed
S&P Futures
5,888.75 -3.75 (-0.06%) Dow Futures
43,050.00 -119.00 (-0.28%) Nasdaq Futures
20,522.50 -19.50 (-0.09%) Russell 2000 Futures
2,244.70 -1.50 (-0.07%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,753.40 -6.40 (-0.23%)
PeptiDream Inc. (4587.T)
Tokyo - Tokyo Delayed Price. Currency in JPY
Follow
As of 11:35AM JST. Market open.
| Previous Close | 2,842.50 |
| Open | 2,854.00 |
| Bid | 2,834.00 x 0 |
| Ask | 2,838.00 x 0 |
| Day's Range | 2,808.00 - 2,865.00 |
| 52 Week Range | 1,039.00 - 3,060.00 |
| Volume | |
| Avg. Volume | 942,453 |
| Market Cap | 367.839B |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | 16.98 |
| EPS (TTM) | 167.10 |
| Earnings Date | Nov 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jun 28, 2011 |
| 1y Target Est | 3,142.90 |
Business WireNCC and PeptiDream Announce the First Dosing of 64Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma
KAWASAKI, Japan, June 04, 2024--National Cancer Center and PeptiDream Inc.:
Business WirePeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis
KAWASAKI, Japan, April 30, 2024--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter "PeptiDream") (Tokyo: 4587) today announced an expansion of its peptide discovery collaboration with Swiss-based Novartis Pharma AG ("hereinafter Novartis") (NYSE: NVS). Under the multi-program agreement, PeptiDream will use its proprietary Peptide Discovery Platform System ("PDPS®") technology to identify and optimize novel macrocyclic pepti
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.